Abingworth — 2015 Investments
1 investments dated 2015 · listed companies and verified rows first · show all
Gensight Biologics S.Agensight-biologics.comin𝕏Jul 2015SEC filingmedium confidence
GenSight Biologics is a clinical-stage biotechnology company developing gene therapies for retinal and neurodegenerative diseases, using mitochondrial targeting sequence and optogenetics technologies.
BiotechHealthtechParis, FR
Jean-Philippe Combal(Executive Officer)Michael Stephen Wyzga(Director)Thomas Gidoin(Executive Officer)Didier Pruneau(Executive Officer)Florent Gros(Director)Nitza Thomasson(Executive Officer)
Board seatGenghis Lloyd-Harris· per SEC Form D · $25M raise · filed Jul 2015
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.